Company’s 36-month beta value is 1.31.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CTKB is 119.18M, and currently, short sellers hold a 3.87% ratio of that floaft. The average trading volume of CTKB on September 12, 2024 was 675.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTKB) stock’s latest price update
Cytek BioSciences Inc (NASDAQ: CTKB) has seen a decline in its stock price by -10.02 in relation to its previous close of 5.49. However, the company has experienced a -9.19% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-21 that FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) — Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification.
CTKB’s Market Performance
CTKB’s stock has fallen by -9.19% in the past week, with a monthly drop of -7.66% and a quarterly drop of -20.06%. The volatility ratio for the week is 4.78% while the volatility levels for the last 30 days are 4.38% for Cytek BioSciences Inc The simple moving average for the last 20 days is -9.83% for CTKB stock, with a simple moving average of -27.42% for the last 200 days.
Analysts’ Opinion of CTKB
Many brokerage firms have already submitted their reports for CTKB stocks, with Stephens repeating the rating for CTKB by listing it as a “Overweight.” The predicted price for CTKB in the upcoming period, according to Stephens is $9 based on the research report published on December 14, 2023 of the previous year 2023.
Piper Sandler gave a rating of “Overweight” to CTKB, setting the target price at $20 in the report published on January 06th of the previous year.
CTKB Trading at -14.88% from the 50-Day Moving Average
After a stumble in the market that brought CTKB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.95% of loss for the given period.
Volatility was left at 4.38%, however, over the last 30 days, the volatility rate increased by 4.78%, as shares sank -4.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.64% lower at present.
During the last 5 trading sessions, CTKB fell by -6.99%, which changed the moving average for the period of 200-days by -27.61% in comparison to the 20-day moving average, which settled at $5.47. In addition, Cytek BioSciences Inc saw -45.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTKB starting from Yan Ming, who sale 20,000 shares at the price of $5.87 back on Apr 19 ’24. After this action, Yan Ming now owns 5,988,502 shares of Cytek BioSciences Inc, valued at $117,400 using the latest closing price.
Yan Ming, the CHIEF TECHNOLOGY OFFICER of Cytek BioSciences Inc, sale 1,900 shares at $7.00 during a trade that took place back on Apr 09 ’24, which means that Yan Ming is holding 6,008,502 shares at $13,304 based on the most recent closing price.
Stock Fundamentals for CTKB
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.55 for the gross margin
The net margin for Cytek BioSciences Inc stands at -0.09. The total capital return value is set at -0.06. Equity return is now at value -4.32, with -3.48 for asset returns.
Based on Cytek BioSciences Inc (CTKB), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 0.62. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -16.51.
Currently, EBITDA for the company is -17.11 million with net debt to EBITDA at 9.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.57. The receivables turnover for the company is 4.42for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In a nutshell, Cytek BioSciences Inc (CTKB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
